presumed to mediate pathogenesis by neutralizing GM-CSF and reducing surfactant catabolism by alveolar macrophages ( 10, 13 ) . This form, referred to as autoimmune PAP, comprises 90% of cases ( 13 ) . Primary PAP has also been associated with reduced detection of GM-CSF-R ␤ on myeloid cells ( 14, 15 ) , but defi nitive studies demonstrating heritable deficiency of either GM-CSF or its receptors as the cause of PAP in humans are lacking ( 16 ) . Secondary PAP occurs as a consequence of an underlying disease presumed to impair surfactant clearance by reducing either the numbers or functions of alveolar macrophages ( 9 ) . Hereditary disorders of surfactant production, for example, because of mutations in the genes encoding surfactant protein (SP) -B ( 17 ) , SP-C ( 18 ), or ABCA3 ( 19 ) , exhibit disordered surfactant homeostasis to varying degrees but are distinguished from PAP by their surfactant dysfunction, disruption of alveolar wall architecture, and clinical course ( 20 ) . In this paper, we describe a family in which two children developed primary PAP in association with loss of GM-CSF responsiveness caused by mutations in the gene encoding GM-CSF-R ␣ .
RESULTS AND DISCUSSION Clinical presentation and phenotype
The index patient presented at age six with a 2-yr history of progressive tachypnea and failure to thrive (height and weight were third percentile for age [ Fig. S1 A, available at http:// www.jem.org/cgi/content/full/jem.20080990/DC1]). Gestation, delivery, birth weight (3.66 kg, 50th percentile), and development were all normal, but weight gain slowed by 6 -9 mo as did height by 2 -3 yr. There was no history of cough, fever, chest pain, pneumonia or other pulmonary disease, environmental exposure, or drug use. Both parents were welldeveloped and healthy with no history of lung disease. Examination revealed moderate tachypnea, mild tachycardia, and inspiratory crackles but was otherwise unremarkable. Pulmonary function testing revealed severe restrictive impairment. Oxygen saturation was 88% while breathing room air and decreased while talking or walking a short distance. A diagnosis of PAP was suspected based on chest radiography ( Fig. 1 A ) and established by histopathologic examination of lung tissue ( Fig. 1 B ) . A serum GM-CSF autoantibody test ( 21 ) was negative on two occasions. The patient was transferred to Cincinnati Children ' s Hospital and underwent whole lung lavage therapy with marked symptomatic and radiographical improvement ( Fig. 1 C ) . MCP-1 and M-CSF levels in the lavage were increased compared with healthy controls (supplemental text, available at http://www.jem.org/cgi/content/full/jem .20080990/DC1), which is similar to fi ndings in autoimmune PAP patients and GM-CSF KO mice ( 22, 23 ) .
An inherited defect in GM-CSF receptor function was suspected based on the constellation of histopathology showing well-preserved alveolar wall architecture ( Fig. 1 B ) , the absence of GM-CSF autoantibodies ( 21 ) , and an abnormal CD11b stimulation index test ( 24 ) . Therefore, all immediate family members were evaluated. Because SP is in serum in PAP and levels refl ect lung disease severity ( 25 ) , serum SP-D 
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ter with predominantly lower molecular mass forms compared with the control ( Fig. 2 B ) . The father was heterozygous for normal and lower molecular mass forms. Unexpectedly, the mother exhibited only a normal pattern. To evaluate cellmediated clearance of GM-CSF, blood mononuclear cells from the patient ( Fig. 2 C ) and her sister (Fig. S2 , available at http://www.jem.org/cgi/content/full/jem.20080990/DC1) were incubated with GM-CSF, and both failed to clear GM-CSF in contrast to control and parental leukocytes. The concentration of GM-CSF in lung lavage was markedly increased in the patient compared with healthy controls, in whom it was undetectable ( Fig. 2 D ) . The in vivo concentration of pulmonary GM-CSF in the epithelial lining fl uid of the lungs was estimated to be 6.9 and 27 ng/ml (right and left lungs, respectively) using the urea dilution method ( 26 ) . Pulmonary was measured and found to be increased in the patient compared with her parents and controls ( Fig. 1 D ) . Unexpectedly, the patient ' s 8-yr-old sister, who was previously thought to be healthy, had increased serum SP-D. Subsequent clinical evaluation revealed that the sister had poor growth (height and weight, 10th percentile for age; Fig. S1B ), a diff usion capacity for carbon dioxide of 57% that predicted, and mild patchy ground glass opacities throughout both lungs, which are consistent with a diagnosis of PAP ( Fig. 1 E ) .
Structure and function of the GM-CSF receptor
Flow cytometry indicated that GM-CSF-R ␣ and GM-CSF-R ␤ were present on blood leukocytes in all family members ( Fig. 2 A ) . Western blotting revealed an abnormal electrophoretic pattern for GM-CSF-R ␣ in the patient and her sis- Western blots of PBMC lysates using antibodies to detect GM-CSF-R ␣ or actin as indicated. (C) GM-CSF clearance assay. Blood leukocytes from the patient were unable to remove exogenous GM-CSF added to culture medium at time zero in contrast to leukocytes from two controls that rapidly bound and cleared GM-CSF. Error bars show the means ± SE. (D and E) Measurement of GM-CSF concentration by ELISA. GM-CSF was readily detected in lavage from the patient but was not detected (ND) in lung lavage from nine healthy controls (D). GM-CSF was detected in the serum of affected siblings but not their parents or a control (E). (F) Blood leukocytes isolated from the indicated family members were incubated for 15 min in the absence ( Ϫ ) or presence (+) of 10 ng/ml GM-CSF, followed by Western blotting of cell lysates to detect total STAT5 (STAT5), phosphorylated STAT5 (pSTAT5), or actin. (G) Measurement of the GM-CSF -stimulated increase in CD11b levels on leukocytes in whole blood. The CD11b stimulation index ( 24 ) was calculated as the mean fl uorescence of CD11b on leukocytes incubated with GM-CSF minus that of unstimulated cells divided by that of unstimulated cells and multiplied by 100. (H) Similar to F except that a higher GM-CSF concentration (1,000 ng/ml) was used and cell lysates were immunoprecipitated with anti-STAT5 antibody before Western blotting to detect total STAT5 (STAT5) or phosphorylated STAT5 (pSTAT5). 
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of CSF2RB was similar in all family members and a control (Fig. S4) . Routine cytogenetic analysis was normal in all family members (Fig. S5 ), ruling out a large chromosomal abnormality. Fluorescent in situ hybridization (FISH) demonstrated a deletion in the pseudoautosomal region 1 of the X chromosome in the patient ( Fig. 3 B ) , her sister, and mother (Fig. S6) that was not present in the father ( Fig. 3 B ) . Further evaluation using comparative genomic hybridization (CGH) demonstrated an interstitial deletion encompassing the region from ‫ف‬ 1,610,183 to 2,873,864 bp on one maternal-derived X chromosome in the patient ( Fig. 3 C ) , her sister, and mother (not depicted). High-resolution single-nucleotide polymorphism (SNP) mapping further defi ned this small deletion as extending from 1,308,324 to 2,881,011 bp in one maternal X chromosome ( Fig. 3 D ) and in both siblings (Fig. S7) . Importantly, this deletion encompassed the CSF2RA allele ( Fig. 3 E ) , thereby explaining the unexpected CSF2RA DNA and mRNA sequence results.
These results demonstrate the inheritance of compound heterozygous abnormalities of CSF2RA in both siblings ( Fig. 3 F ) . The G174R mutation present on the paternal X chromosome, localized to the extracellular cytokine binding domain of GM-CSF-R ␣ , alters a potential site of glycosylation and impairs GM-CSF binding and receptor signaling. However, it is unclear if the functional impairment is caused by the change in primary amino acid sequence or loss of glycosylation.
Reproduction of the CSF2RA G174R abnormality
To reproduce the GM-CSF receptor signaling defect identifi ed in this family, plasmids expressing CSF2RB and either CSF2RA G174R or CSF2RA WT were cotransfected into 293 cells. Western blotting showed receptor proteins of the expected size from CSF2RA WT and smaller molecular forms from CSF2RA G174R ( Fig. 4 A ) , which is similar to results for primary leukocytes ( Fig. 2 B ) . Treatment of transduced cell lysates with Peptide: N-Glycosidase F, an amidase that cleaves between the innermost GlcNAc and asparagine residues of high mannose oligosaccharides ( 3 ), resulted in a similar electrophoretic pattern for normal and G174R GM-CSF-R ␣ . This confi rmed the G174R mutation alters N-linked glycosylation ( Fig. 4 A ) by disrupting a functional N-linked glycosylation site and that glycosylation is responsible for the smaller molecular forms from this allele. GM-CSF-R ␤ was expressed in CSF2RB -transfected cells but was undetectable in nontransfected cells (unpublished data). GM-CSF binding studies demonstrated that cells expressing CSF2RA WT and CSF2RB rapidly bound GM-CSF and removed it from the media, whereas cells expressing CSF2RA G174R and CSF2RB or CSF2RB alone GM-CSF was also increased in CSF2RB -defi cient mice (Fig. S3) , confi rming the relationship between GM-CSF receptor dysfunction and increased pulmonary GM-CSF levels. Serum GM-CSF was increased in both aff ected siblings and undetectable in both parents and control, indicating that the abnormality was systemic ( Fig. 2 E ) . GM-CSF receptor function was impaired in both aff ected siblings, as shown by reduced GM-CSF -stimulated phosphorylation of STAT5 ( Fig. 2 F ) and failure of GM-CSF to increase CD11b levels on leukocytes from the patient compared with controls ( Fig. 2 G ) .
The slower-than-expected rate of progression of PAP in both aff ected siblings led us to hypothesize that the GM-CSF-R ␣ abnormality may not completely abolish GM-CSF signaling. This was confi rmed by incubation of primary blood mononuclear cells with a higher concentration of GM-CSF (1,000 ng/ml), which resulted in partial receptor signaling as shown by an increase in phosphorylated STAT5 ( Fig. 2 H ) . Thus, although both GM-CSF-R ␣ and ␤ chains were present on leukocytes in all family members, in the two aff ected siblings, the GM-CSF-R ␣ chain was structurally abnormal, which severely reduced but did not completely abolish GM-CSF binding and GM-CSF -dependent signaling and cellular functions.
Genetic analysis of the GM-CSF receptor
The nucleotide sequence of the CSF2RA gene in genomic DNA from both siblings revealed a single G → A point mutation in exon 7 that encoded a nonconservative amino acid change (glycine to arginine) at position 174, G174R ( Fig. 3 A ) . This change alters one of the 11 potential sites of N-glycosylation, which is required for GM-CSF receptor function ( 3, 27 ) . The father was heterozygous for mutant CSF2RA G174R and WT ( CSF2RA WT ) alleles ( Fig. 3 A ) , whereas only the CSF2RA WT sequence was detected in the mother ( Fig. 3 A ) . The sequence of CSF2RA in leukocyte messenger RNA (mRNA) was similar to the respective DNA sequence for each family member, even when cDNA was overamplifi ed to detect potentially underrepresented mRNA sequences (unpublished data). This absence of a normal sequence for CSF2RA exon 7 in both siblings and the absence of the point mutation in the mother suggested that one maternal CSF2RA allele may be deleted in the patient, her sister, and their mother. The nucleotide sequence of CSF2RB in leukocyte mRNA from all family members was normal (unpublished data).
PCR amplifi cation demonstrated a reduced copy number of CSF2RA in genomic DNA from both siblings and their mother compared with the father and a healthy control (Fig. S4 , available at http://www.jem.org/cgi/content/full/ jem.20080990/DC1). In contrast, the genomic copy number tion of CSF2RA G174R / CSF2RB -transduced cells with higher concentrations of GM-CSF in the range of those observed in the index patient gave results similar to those obtained with primary leukocytes and clearly demonstrated a modest dose-dependent increase in STAT5 phosphorylation, which is consistent with a partial rescue of the signaling abnormality ( Fig. 4 D ) .
Clinical relevance of the CSF2RA G174R mutation Our fi ndings demonstrate that familial primary PAP in humans is caused by compound heterozygous abnormalities of CSF2RA , including loss of heterozygosity and a function-altering point mutation that severely reduces GM-CSF receptor signaling. These are the fi rst results to demonstrate familial primary PAP in humans and that GM-CSF-R ␣ is critical for surfactant homeostasis. They extend previous fi ndings that PAP is caused by the absence of GM-CSF or GM-CSF-R ␤ in mice ( 4 -6 ) or is specifi cally associated with the presence of neutralizing GM-CSF autoantibodies or a reduction in alveolar macrophage numbers or function in humans ( 9, 10 ) . The allelic frequency of these mutations has not been determined but may be rare given that autoantibodies against GM-CSF account for most individuals with PAP.
Both aff ected siblings had impaired pulmonary function and failure to thrive, supporting the conclusion that prolonged respiratory insuffi ciency in children retards growth. Important to this conclusion is the observation that Xp22.33 deletion did not include the SHOX ( short stature homeobox ) gene, the deletion of which impairs growth ( 28 ) . Further, heterozygous loss of CSF2RA in the mother did not impair growth. Early results suggest that whole lung lavage therapy was followed by an increase in growth acceleration in the index patient.
This study highlights the usefulness of several novel biomarkers in the diagnostic evaluation of PAP. The combination of a negative GM-CSF autoantibody test ( 29 ) and an abnormal CD11b stimulation index ( 24 ) predicted the GM-CSF receptor dysfunction, which was confi rmed by the lack of GM-CSF binding and defective GM-CSF receptor signaling. GM-CSF levels were increased in lung lavage from the patient and, in serum from the patient and her sister, compared with family members and healthy controls. Because primary PAP is presumed to be caused by a defect in GM-CSF regulation of alveolar macrophage surfactant catabolism ( 9, 10 ), an elevated serum GM-CSF level may be useful as a biomarker to distinguish primary PAP caused by GM-CSF autoantibodies (90% of all cases of PAP) ( 9, 10, 13, 30 ) from PAP caused by GM-CSF receptor dysfunction (this study; references 14 -16 ) and PAP caused by GM-CSF defi ciency ( 4, 5 ) (not yet reported in humans). Finally, an increased serum SP-D level predicted the occurrence of PAP in the sister, which was confi rmed by subsequent clinical and radiographical evaluation.
The slow progression and diff erences in severity of the lung disease between aff ected siblings with the same CSF2RA mutations and GM-CSF-R ␣ dysfunction indicates that penetrance is important in familial PAP because of GM-CSF receptor defects. The increased levels of GM-CSF likely refl ect im paired clearance but are also consistent with interruption of a did not clear GM-CSF ( Fig. 4 B ) . Cotransfection of CSF2RB together with CSF2RA WT , but not with CSF2RA G174R , resulted in expression of functional GM-CSF receptors as demonstrated by GM-CSF -dependent phosphorylation of STAT5 only with the former combination ( Fig. 4 C ) . Incuba- with published sequences (from GenBank/EMBL/DDBJ under accession nos. NM_006140.3 and BC070085 , respectively). The relative copy number of CSF2RA and CSF2RB genes among family members and a healthy control was measured by amplifi cation of genomic DNA using PCR with gene-specifi c oligonucleotides followed by analysis of products by electrophoresis on 2% agarose gels. Experimental methods for measuring gene copy number, evaluating the genes encoding SP-B, SP-C, and ABCA3 ( 19, 31 ) for function-altering mutations, cytogenetic analysis, CGH analysis, FISH, and high-resolution SNP array analysis ( 32 ) are described in the supplemental Materials and methods (available at http://www.jem .org/cgi/content/full/jem.20080990/DC1).
Reproduction of the GM-CSF receptor defect. The methods used to clone and express mRNA transcripts encoding GM-CSF-R ␣ and ␤ chains in cultured cells and evaluate protein glycosylation are described in the supplemental Materials and methods.
Statistical analysis. Numeric data are presented as means ± SE. Statistical comparisons were made with Student ' s t test for two-group comparisons and with one-way analysis of variance with posthoc analysis according to the Holm-Sidak method for multiple-group comparisons. P-values of < 0.05 were considered to indicate statistical signifi cance.
Online supplemental material. Fig. S1 shows normalized growth curves for the index patient and her sister. Fig. S2 shows GM-CSF binding and clearance by blood leukocytes from aff ected and unaff ected family members and control. Fig. S3 shows increased pulmonary GM-CSF levels in GM-CSF receptor ␤ chain ( Csf2rb ) KO mice. Fig. S4 shows evaluation of CS-F2RA and CSF2FB gene copy number by PCR amplifi cation. Fig. S5 shows karyotypes of high-resolution GTG-banded chromosomes. Fig. S6 shows evaluation of heterozygosity at the CSF2RA locus by FISH. negative-feedback regulatory loop. Results strongly suggest that the high levels of pulmonary GM-CSF present in epithelial lining fl uid result in a reduced but not abrogated receptor signaling and provide a molecular explanation the slow progression of PAP in both aff ected siblings. It is currently unclear if the level of increased pulmonary GM-CSF correlates with disease severity. They also suggest that aerosolized delivery of GM-CSF to the lungs may be therapeutic because this approach could theoretically achieve pulmonary GM-CSF levels several thousand -fold higher than endogenous levels measured in the patient and 20-fold higher than levels that appeared to completely restore GM-CSF receptor signaling in the transfection experiments. BM transplantation and CSF2RA gene transfer represent other potentially therapeutic approaches.
The identifi cation of mild PAP in the older sister provides a unique and important opportunity to observe PAP at a very early stage of disease development. Finally, this case exemplifi es the utility of a collaborative approach to the diagnosis and treatment of individuals with very rare diseases involving geographically disparate clinical centers and the benefi t derived from integrating basic science, clinical medicine, and translational research.
MATERIALS AND METHODS

Participants.
The institutional review board of the Cincinnati Children ' s Hospital Medical Center approved the study, and all participants gave written informed consent or assent. Detailed case histories and laboratory data for the participants are included in the supplemental text (available at http:// www.jem.org/cgi/content/full/jem.20080990/DC1).
GM-CSF receptor structure and function. GM-CSF receptors were evaluated by fl ow cytometry using antibodies recognizing GM-CSF-R ␣ (BD) or ␤ (Santa Cruz Biotechnology, Inc.) and by Western blotting ( 7 ) with chain-specifi c antibodies (Santa Cruz Biotechnology, Inc.). The eff ects of glycosylation on GM-CSF-R ␣ were evaluated by incubating cell lysates with PNGase F (New England Biolabs, Inc.) ( 3 ). Actin was measured as a loading control using anti-actin antibodies (Santa Cruz Biotechnology, Inc.). To evaluate receptor-mediated clearance of GM-CSF, Ficoll-purifi ed blood leukocytes or 293 cells (American Type Culture Collection) were cultured in DMEM containing 10% fetal bovine serum and human GM-CSF (Leukine; Bayer) at 1 ng/ml. At subsequent times, GM-CSF was measured in the culture medium by ELISA (R & D Systems) ( 24 ) . To evaluate GM-CSF receptor signaling, heparinized blood was incubated with or without 10 ng/ml of human GM-CSF Leukine for 15 min. After lysing RBC, leukocytes were evaluated by Western blotting ( 24 ) using anti -human STAT5 (Santa Cruz Biotechnology, Inc.) and anti -phospho-STAT5 (Millipore) antibodies. The CD11b stimulation index was measured as previously described ( 24 ) .
ELISA. SP-D, GM-CSF, MCP-1 (monocyte chemotactic protein-1), M-CSF, and urea were measured using commercial ELISA kits (BioVendor, R & D Systems, BD, R & D Systems, and BioAssay Systems, respectively) ( 24 ) . The concentration of cytokines in epithelial lining fl uid of the lungs was estimated by multiplying the concentration in lavage fl uid by the ratio of urea concentrations in serum and lavage fl uid ( 26 ) .
Genetic analysis. Genomic DNA or total mRNA was purifi ed from blood leukocytes with commercially available kits (QIAGEN). The PCR was used to generate products spanning exons and fl anking intronic sequences (genomic DNA) or the coding sequences and 5 Ј and 3 Ј fl anking untranslated sequences (mRNA) of the CSF2RA and CSF2RB genes, which were then analyzed by direct sequencing. The resulting sequences were compared
